ABSTRACT
The extravillous trophoblast (EVT) cell lineage is a key feature of placentation and successful pregnancy. Knowledge of transcriptional regulation driving EVT cell development is limited. Here, we mapped the transcriptome and epigenome landscape as well as chromatin interactions of human trophoblast stem (TS) cells and their transition into EVT cells. Integration of chromatin accessibility, long-range chromatin interactions, transcriptomic, and transcription factor (TF) binding motif enrichment enabled identification of TFs and regulatory mechanisms associated with EVT cell development. Functional roles for TFAP2C, SNAI1, and EPAS1 in the regulation of EVT cell development were elucidated. EPAS1 was identified as an upstream regulator of key EVT cell TFs, including ASCL2 and SNAI1 and together with its target genes, was linked to pregnancy loss and birth weight. Collectively, we have revealed activation of a dynamic regulatory network that provides a framework for understanding EVT cell specification in trophoblast cell lineage development and human placentation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was supported by an NRSA postdoctoral fellowship to K.M.V. from the National Institutes of Health (F32HD096809), grants from the National Institutes of Health (HD020676, HD079363, HD099638, HD105734, GM146966, HG012422), the Sosland Foundation, KAKENHI Grant Number 19H05757, and AMED Grant Number JP22gm1310001. E.G holds the Roberta D. Harding & William F. Bradley, Jr. Endowed Chair in Genomic Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Childrens Mercy Institutional Review Board (study # 11120514). Informed written consent was obtained from the recurrent pregnancy loss participants before study inclusion. Prior approval was granted by the respective local human research ethics review committees at the Mount Sinai Hospital and the University of Kansas Medical Center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the results section, Figures 1-5, supplementary figures 9, 12, 15, 24 and corresponding figure legends.
Data Availability
Raw and processed sequencing data from ATAC-Seq, RNA-Seq and Hi-C have been submitted to the NCBI Gene Expression Omnibus (GEO). Processed data can be visualized in the UCSC Genome Browser. The ChIP-seq data of histone modifications are deposited in Japanese Genotype-phenotype Archive (JGA).
